Nurix Therapeutics Shares Decline Following Sanofi's Decision to Discontinue Inflammatory Disease Drug Studies
Nurix Therapeutics (NRIX) experienced significant stock price declines in both post-market and pre-market trading following an announcement regarding its partnership with Sanofi (SNY). The French pharmaceutical giant has decided to discontinue clinical studies for an experimental therapy aimed at treating inflammatory diseases. The decision marks a setback for the Nurix-Sanofi collaboration, as the discontinuation of these specific studies removes a key development pathway for the experimental drug. Investors are reacting to the loss of momentum and potential reduction in future milestone payments or collaborative value associated with this particular therapeutic candidate.
Topics: clinical trial discontinuation pharmaceutical partnership stock price movement